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ABSTRACT
Background: In the past, strains of Staphylococcus
aureus have evolved, expanded, made a marked
clinical impact and then disappeared over several
years. Faced with rising meticillin-resistant S aureus
(MRSA) rates, UK government-supported infection
control interventions were rolled out in Oxford
Radcliffe Hospitals NHS Trust from 2006 onwards.
Methods: Using an electronic Database, the authors
identiﬁed isolation of MRS among 611434 hospital
inpatientsadmittedtoacutehospitalsinOxford,UK,1April
1998 to30June 2010.Isolationrateswere modelled using
segmented negative binomial regression for three groups
of isolates: from blood cultures, from samples suggesting
invasion (eg, cerebrospinal ﬂuid, joint ﬂuid, pus samples)
and from surface swabs (eg, from wounds).
Findings: MRSA isolation rates rose rapidly from
1998 to the end of 2003 (annual increase from blood
cultures 23%, 95% CI 16% to 30%), and then declined.
The decline accelerated from mid-2006 onwards (annual
decrease post-2006 38% from blood cultures, 95% CI
29% to 45%, p¼0.003 vs previous decline). Rates of
meticillin-sensitive Sa u r e u schanged little by
comparison, with no evidence for declines 2006 onward
(p¼0.40); by 2010, sensitive Sa u r e u swas far more
common than MRSA (blood cultures: 2.9 vs 0.25;
invasive samples 14.7 vs 2.0 per 10000 bedstays).
Interestingly, trends in isolation of erythromycin-
sensitive and resistant MRSA differed. Erythromycin-
sensitive strains rose signiﬁcantly faster (eg, from blood
cultures p¼0.002), and declined signiﬁcantly more
slowly (p¼0.002), than erythromycin-resistant strains
(global p<0.0001). Bacterial typing suggests this reﬂects
differential spread of two major UK MRSA strains (ST22/
36), ST36 having declined markedly 2006e2010, with
ST22 becoming the dominant MRSA strain.
Conclusions: MRSA isolation rates were falling before
recent intensiﬁcation of infection-control measures.
This, together with strain-speciﬁc changes in MRSA
isolation, strongly suggests that incompletely
understood biological factors are responsible for the
much recent variation in MRSA isolation. A major,
mainly meticillin-sensitive, S aureus burden remains.
INTRODUCTION
Staphylococcus aureus has a huge impact in
healthcare.
1 2 It is a clonal organism: much
disease is caused by a small number of groups
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ARTICLE SUMMARY
Article focus
- Multiple infection control interventions in UK
hospitals were rolled out in 2005e2010.
- Over the same time period, a decline in MRSA
isolations has been noted. The relationship
between these two events is unclear and was
investigated using an observational study in
a group of hospitals.
Key messages
- MRSA isolation rates from blood culture, surface
swabs and samples suggesting invasive disease
declined from 2003 onwards, compatible with
national trends.
- Rates of meticillin-sensitive S aureus changed
little by comparison. Analysis of resistance
proﬁles, together with genotyping of archival
collections, suggests a differential decline in the
two dominant MRSA strains, ST22 and ST36.
- MRSA isolation rates were falling before recent
intensiﬁcation of infection-control measures.
- This, together with strain-speciﬁc changes in
MRSA isolation, strongly suggests that incom-
pletely understood biological factors are respon-
sible for the much recent variation in MRSA
isolation.
- A major, mainly meticillin-sensitive, S aureus
burden remains.
Strengths and limitations of this study
- A large hospital with trends in MRSA blood
culture isolation similar to the national trends
was studied, and data are available not only for
blood cultures but also for all other samples.
- Archival collections of samples and detailed
epidemiological and typing data are all available.
- The data are observational.
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Open Access Researchof highly successful, very closely related organisms; such
groups are termed clonal complexes
3 and vary in their
virulence and disease manifestations.
45
When and how new successful S aureus clones arise is
an incompletely understood process which has repeat-
edly had a major clinical impact. An early example of
a successful and virulent meticillin-sensitive clone of
sequence-type 30 (ST30) caused serious wound infec-
tions and drove initial infection-control investment in
the 1950s; the epidemic ended some years later.
6
Subsequently meticillin-resistant S aureus (MRSA) clones
emerged, expanded and then declined for unknown
reasons,
7 sometimes being replaced by different MRSA
strains.
5 In the UK, a national epidemic of two successful
clones, designated EMRSA 15 and 16 (ST22 and ST36,
respectively) has been responsible for over 95% of cases
from the mid-1990s
8; by 2006, MRSA was responsible for
15% of all hospital-associated infections and affected
about 1.3% of UK inpatients.
9
As infection rates, patient concern and costs all rose,
10
MRSA control, and the wider ﬁeld of infection control,
became a major focus of the UK government. Multiple
initiatives were centrally planned and locally delivered,
with implementation centrally monitored via process-
based reporting systems across England, as speciﬁed in
the Health Act 2006 legislation. The impact on disease
was assessed via a mandatory MRSA-bacteraemia-
reporting scheme.
10 Initiatives focused both on
management structures prioritising infection control in
high-level decision-making and on patient-level inter-
ventions: examples included the Winning Ways guidance
document (2003),
11 the Clean Your Hands Campaign
(2004),
12 the Saving Lives programme,
13 Public Service
Agreements which from 2004 onward contained
a commitment to halve MRSA bacteraemia,
10 the Health
Act 2006,
10 and a revised Saving Lives Campaign (2007)
featuring ‘high impact interventions’ including manda-
tory use of improved line insertion processes and pre-
and perioperative management.
13 Finally, MRSA
screening of elective admissions was introduced from
April 2009 across the UK NHS, to be extended to all
admissions by 2010.
13
Mandatory reporting has shown a steep decline in
MRSA isolations from blood cultures across England
from 2005 onwards. Meeting UK government targets for
MRSA bacteraemia declines has been hailed as
a triumph for a ‘zero tolerance approach’ supported by
a well-resourced, centrally mandated, coordinated
infection control initiative.
10 However, similar declines
in meticillin-sensitive S aureus (MSSA) bacteraemia have
not been seen, although many interventions would be
expected to impact all S aureus infections. Additionally,
while multicentre quality-improvement studies with
contemporaneous controls have documented declining
MRSA rates, attribution of the decline to interventions
proved difﬁcult.
14 It is possible, therefore, that (as
occurred in the past)
7 some changes in S aureus inci-
dence may have occurred independently of intervention.
In view of this, we carefully examined rates of MRSA and
MSSA isolation over 12 years in our NHS trust acute
hospitals, in relation to the introduction of the different
infection-control interventions.
METHODS
This study was a prespeciﬁed approved analysis project
within the Infections in Oxfordshire Research Database,
an anonymised linked electronic database including
microbiology and patient data from Oxfordshire,
approved by the Oxford Research Ethics Committee and
the National Information Governance Board. We
included admissions to all acute Oxford hospitals in the
Oxford Radcliffe Hospital NHS Trust (John Radcliffe,
Churchill, Radcliffe Inﬁrmary) and specimens from
these inpatients submitted for testing between 1 April
1998 and 30 June 2010 (total 611434 inpatients). We did
not include specimens or admissions from the Nufﬁeld
Orthopaedic Centre (NOC) NHS Trust, a small unit
focusing mainly on elective bone and joint surgery, the
Horton General Hospital (a district hospital near
Banbury, north Oxfordshire) or any other mental-health
NHS Trusts or private hospitals. To allow for variation in
speciﬁc times recorded on the underlying data sources,
following previous analyses a patient was considered to
be ‘within hospital’ when the date of specimen collec-
tion was between 24 h before the time of hospital
admission on the Patient Administration System and
24 h after the stated discharge time.
15 Haemodialysis and
chemotherapy sessions were considered as ‘within
hospital’. Deﬁned in this way, the patient population
covered by Oxfordshire Research Database remained
constant over the study period.
We considered clinical specimens taken for microbio-
logical testing in three exclusive categories:
1. blood cultures;
2. cultures from other samples suggestive of invasive
disease (such as abscesses, peritoneal, pleural or joint
ﬂuid, cerebrospinal ﬂuid, bronchoalveolar lavage
samples);
3. surface cultures (deﬁned by laboratory standard
operating procedures as locations not expected to
be sterile, such as wounds).
Discrimination between (2) and (3) was made by
biomedical scientists on specimen receipt in the labo-
ratory based on clinical details provided. We did not
include MRSA-screening samples, only samples sent
because of clinically suspected infection. Microbiological
processing was performed in the Oxford Radcliffe
Hospitals microbiology laboratory, which is approved by
Clinical Pathology Accreditation. Processing was essen-
tially as recommended by the Health Protection Agency
standard methods.
16 Macrolide sensitivity testing was
performed using a standardised comparative disc diffu-
sion method throughout the entire study period. Within
speciﬁc research studies, multilocus sequence typing was
performed as described.
17 When multiple isolations
occurred from the same kind of specimen (eg, blood
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one isolation, a deduplication policy used by national
mandatory MRSA surveillance.
10 We used overnight stays
(termed the KH03 statistic), a measure recommended by
the UK government,
10 as denominators for isolations of
MRSA and MSSA.
Bias
Our study design is observational, based on specimens
taken for clinical indications. Changes in clinical prac-
tice in deﬁned clinical areas are therefore of potential
concern. Our main approach to reducing the inﬂuence
of bias was to look for consistency in ﬁndings across
multiple sample groups. Further, to identify whether
reductions in rates in particular could be a consequence
of reduced sampling, we also estimated rates of clinical
specimen taking (using the same 14-day deduplication)
across the study period.
Statistical methods
We modelled quarterly counts of MRSA and MSSA from
patients admitted to the ORH NHS Trust using negative
binomial regression models with quarterly denominator
counts as an offset, estimated using maximum likelihood
with the R 2.11 glm.nb function. Contrast estimates used
estimable (R gmodels package). We identiﬁed change
points for trends in MRSA and MSSA isolation from each
type of specimen from visual inspection of ﬁtted natural
cubic splines with three knots (at the 10th, 50th and 90th
percentiles),
18 and from comparisons of Akaike Infor-
mation Criterion from grid search across all possible one
and two joinpoint models, considering joinpoints every
quarter from September 1998 to September 2009. As
isolation from blood cultures was our primary outcome
(following the mandatory surveillance scheme) we
deﬁned calendar periods according to changes in MRSA
bacteraemia, and then compared trends in MRSA and
MSSA in these same periods using stacked regression
with robust variance adjustment.
Rates were also calculated according to whether the
MRSA strain was resistant or sensitive to erythromycin.
We estimated rates of ST22 and ST36 MRSA assuming
that (see Results) (1) all MRSA strains were represented
by ST22 and ST36 only; (2) all erythromycin-sensitive
MRSA strains were ST22; and (3) ST22 consisted of
similar proportions of erythromycin-sensitive and -resis-
tant MRSA strains. Sensitivity analyses replaced (4) with
the upper and lower 95% conﬁdence limits for the
estimated proportions of erythromycin-sensitive and
-resistant ST22.
RESULTS
Participants and outcomes
Between April 1998 and June 2010, 611434 individuals
were admitted to ORH a total of 1971482 times; there
were 3681791 overnight bedstays and 354952 emer-
gency admissions. After deduplication, there were a total
of 44541 S aureus isolations from blood, other invasive or
surface samples; 29122 MSSA isolations from 11272
individuals, and 15419 MRSA isolations from 4903
individuals. Both MRSA and MSSA were isolated from
852 individuals at some point during the 12-year period.
There were more men with both MSSA and MRSA.
The age distribution was typical of that described
nationally,
10 and as previously described,
19 about 10% of
S aureus isolations were from blood (table 1).
Expansion and decline phases of the MRSA epidemic
Figure 1 shows that in blood cultures, other invasive
samples, and surface swabs obtained from hospital
inpatients over 12 years the MRSA epidemic expanded,
remained static and then declined. Segmented regres-
sion modelling suggested inﬂections at two points: the
ﬁrst occurred at some time before April 2004, with the
most likely change from expansion to decline in blood
cultures isolation occurring in October 2003. Spline-
based curve-ﬁtting yielded similar conclusions (not
shown). The decline in isolation from surface cultures
may have started slightly earlier (ﬁgure 1). There was
also statistical evidence for a steepening of the decline
from July 2006 onwards (p¼0.003, 0.007 and <0.0001 for
blood, other invasive and surface samples respectively).
In subsequent analyses, in order to compare isolations
from different groups of samples over the same periods
of time, we deﬁned three calendar periods according
to the optimal change points for MRSA bacteraemia
(ﬁgure 1). For example, other invasive MRSA incidence
rate ratios (IRRs) per annum were 1.13 (ie, a 13%
increase per annum, 95% CI 1.09 to 1.18) in the ﬁrst
(expansion) phase to October 2003, 0.90 (95% CI 0.84
to 0.97), in the initial decline phase from October 2003
through July 2006, and 0.76 (0.71, 0.82) in the third
(steeper decline) phase from July 2006 onward (latter
two rates differ; p¼0.007). Trends in isolations
from surface samples and blood cultures were similar
(ﬁgure 1B,D), with initial increases and post-2006 IRRs
in blood cultures of 1.23 (1.16e1.30) and 0.62
(0.55e0.71), respectively.
Changing sampling rates
Over the 12 years, overall rates of collection of sampling
changed little during the expansion, decline and rapid
decline phases for the epidemic (ﬁgure 1F). Trends in
invasive sample taking, in particular, were statistically
signiﬁcant at p<0.01 given large numbers, although
trends in blood-culture taking were not. All sampling
trends were small in magnitude (IRRs 0.95 to 1.05; 95%
CI 0.94 to 1.07). Thus, changes in sampling rates were
unlikely to explain the much larger changes in MRSA
isolation rates observed.
Local interventions and change in MRSA isolation rates
At the start of the study period, the only S aureus speciﬁc
control measure in place was risk-based MRSA screening,
and mupirocin decontamination in renal patients. Use
of antimicrobial impregnated central lines was initiated
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published in 2004 and 2005; apart from stopping
mupirocin decontamination in renal patients in 2005,
only in 2006 were multiple initiatives, including wide-
spread use of alcohol hand gels, put into place in the
study hospitals. Enhanced intravascular line speciﬁc
interventions followed in 2007, and from late 2008
decontamination programmes were progressively
implemented (table 2). Thus, the end of the MRSA
‘expansion phase’ occurred around the time of the ﬁrst
Department of Health initiative but preceded the local
interventions mandated by this and subsequent investi-
gations by more than 1 year; the steeper decline phase
from 2006 began at the same time as the initial hospital-
wide interventions.
Changes in meticillin-sensitive Staphylococcus aureus
isolation
By 2010, MSSA isolation was far more common than
MRSA (for blood cultures: 2.9 vs 0.25; for invasive
samples 14.7 vs 2.0 per 10000 bedstays, ﬁgure 1). We
analysed MSSA in the same three time periods identiﬁed
for the MRSA epidemic, for the purposes of comparison.
By contrast with the changes seen in MRSA isolation,
changes seen in MSSA were modest (ﬁgure 1C,E).
For example, during the steep decline phase of
MRSA, MSSA isolation from blood cultures did
not change signiﬁcantly in the hospital overall (IRR
0.97, 95% CI 0.90 to 1.04). Indeed, small increases in
MSSA isolation from invasive samples were seen in the
later years of the study (ﬁgure 1C,E; IRR 1.07, 95% CI
1.03 to 1.11), although this may be in part due to
enhanced sampling. Since multiple interventions
(including use of alcohol gels and enhanced intravas-
cular line precautions) might be expected to decrease
both MRSA and MSSA rates (table 2), these results were
surprising.
Decline in MRSA isolation is strain-speciﬁc
Another unanticipated observation came from routine
surveillance of antimicrobial resistance patterns, with
signiﬁcant changes in the proportion of MRSA strains
reported as erythromycin-resistant; ﬁgure 2A shows the
results for blood cultures. Although both erythromycin-
sensitiveand-resistantMRSAincreasedfrom1998to2003,
the increases were greater for erythromycin-sensitive
Table 1 Characteristics of Staphylococcus aureus cases
Meticillin-resistant
(N[15419) n, col %
Meticillin-sensitive
(N[29122) n, col %
Percentage meticillin-
resistant (row %)
Total samples 15419 (100) 29122 (100) 35
Isolated from
Blood 1627 (11) 2934 (10) 36
Invasive samples 4423 (29) 10208 (35) 30
Surface samples 9369 (61) 15980 (55) 37
Isolation
First 4903 (32) 11272 (39) 30
Subsequent 10516 (68) 17850 (61) 37
Gender
Not male* 6197 (40) 12963 (45) 32
Male 9222 (60) 16159 (55) 36
Age
Early neonatal (0e6 days) 36 (0.2) 764 (3) 4
Late neonatal (7e28 days) 48 (0.3) 332 (1) 13
29 days to 4 years 258 (2) 2864 (10) 8
5e9 years 60 (0.4) 830 (3) 7
10e19 years 237 (2) 1839 (6) 11
20e29 years 531 (3) 2564 (9) 17
30e39 years 778 (5) 2802 (10) 22
40e49 years 1123 (7) 2792 (10) 29
50e59 years 1965 (13) 3158 (11) 38
60e69 years 2761 (18) 3536 (12) 44
70e79 years 3836 (25) 3833 (13) 50
80e89 yearsyears 3018 (20) 2936 (10) 51
90e99 years 746 (5) 682 (2) 52
Location of specimen
Intensive therapy unit 7873 (39) 15078 (44) 34
Haemodialysis 5760 (28) 6276 (18) 48
Nosocomial 4906 (24) 5227 (15) 48
Admission 1734 (9) 7524 (22) 19
*Gender missing in two cases.
4 Wyllie DH, Walker AS, Miller R, et al. BMJ Open 2011;1:e000160. doi:10.1136/bmjopen-2011-000160
Decline of meticillin-resistant Sa u r e u sin Oxfordshire hospitals(IRR 1.45, 95% CI 1.26 to 1.66) than for -resistant
MRSA (IRR 1.19, 95% CI 1.12 to 1.27) (p¼0.002). During
the rapid decline phase, the opposite trend was
observed (ﬁgure 2A,B,p ¼0.002 for difference in trend
between erythromycin-resistant and -sensitive isolates).
Trends in invasive and surface isolates were similar
(ﬁgure 3).
Since it is known that two clones of MRSA, ST22 and
ST36 have dominated the UK’s MRSA epidemic,
8 we
considered whether these changes might reﬂect differ-
ential clonal expansion in MRSA. To do this, we esti-
mated rates of ST22 and ST36 MRSA by comparing
multilocus sequence types of two archival collections of
nosocomial bacteraemia Oxford MRSA strains
17 20 with
erythromycin sensitivities from 1999 to 2007. As
expected from national data,
8 all but ﬁve of the 138
samples (4%, 1/29 (3%) in 1999, 4/114 (4%) in 2007)
were ST22 or ST36: we therefore assumed that all
MRSA strains were represented by ST22 and ST36 only.
Only 1/51 erythromycin-sensitive samples was ST36 (1/5
in 1999, 0/46 in 2007; two and one being non-ST22/36
respectively): we therefore assumed all erythromycin-
sensitive strains were ST22. Fifty-four of 101 (53%; 95%
CI 43% to 63%) of ST22 were erythromycin-resistant
(1/4 (25%) in 1999, 53/97 (55%) in 2007): we therefore
assumed that 53% and 47% of ST22 were erythomycin-
resistant and -sensitive respectively, with sensitivity
analyses based on the 95% CI limits. With these
assumptions, although estimated isolation of both ST22
and ST36 from blood cultures declined from 2006
onwards, declines in blood cultures were greater in ST36
than in ST22 (ﬁgure 2), with the steeper rate in 2006
appearing to be ST36-speciﬁc. Compatible with the
pattern observed in blood, declines appeared largely
restricted to ST36 (based on the relationships derived
from analysis of blood-culture collections) in isolations
from invasive samples and surface swabs (data not
shown).
Figure 1 Isolation of meticillin-resistant Staphylococcus aureus (MRSA) and meticillin-sensitive Staphylococcus aureus (MSSA)
over a 12-year period: (A) interventions and government initiatives over 12 years, along with rates of isolation of (B) MRSA and (C)
MSSA in hospital. Points indicate quarterly rates: solid lines are trends in each time period from negative binomial regression.
Denominators are the KH03 overnight bedstay statistic. In (B), the optimal change points for MRSA isolation from each group of
isolates is shown (dots) along with the range of change points yielding similar model ﬁts (difference in Akaike Information
Criterion<3.84). These change points divide the 12-year period into three periods; rates of isolation in each of these periods are
shown for (D) MRSA, (E) MSSA and rates of sampling in (F). Evidence for variation in trends in ﬁrst versus second and second
versus third periods respectively: MRSA blood <0.0001, 0.003; MRSA surface <0.0001, <0.0001; MRSA invasive <0.0001,
0.007; MSSA blood 0.79, 0.70; MSSA surface <0.0001, 0.04; MSSA invasive 0.001, 0.90 (*p<0.01 for the comparison shown).
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Date Intervention
Expected impact on
MRSA MSSA
Haemodialysis and renal unit
Feb 1996 Renal dialysis patients screened for MRSA every 3 months and all
MRSA-positive renal dialysis patients decontaminated
Reduce
Jun 2000 Decontamination of all patients with Tessio lines (regardless of
MRSA/MSSA status)
Reduce Reduce
Aug 2005 Routine decontamination for MRSA-positive renal dialysis patients
stopped
Increase
Sep 2006 Intensive audits assessing compliance with line insertion and after
care in renal (and intensive care) units
Reduce Reduce
Jul 2007 Waiting time for ﬁstula formation for renal dialysis changed from
a 6-month wait to a 4-week wait
Reduce Reduce
Intensive care unit
Feb 1996 Intensive therapy unit patients screened for MRSA at admission
(risk-based)
Reduce
Jun 2002 Antimicrobial impregnated lines introduced Reduce Reduce
Sep 2006 Intensive audits assessing compliance with line insertion and
after care in intensive care (and renal) unit
Reduce Reduce
Sep 2007 Central line insertion pack and minimum standards implemented
in intensive care and theatres
Reduce Reduce
Aug 2008 Decontamination of all patients in intensive therapy unit (regardless
of MRSA/MSSA status)
Reduce Reduce
Hospital-wide
Mar 1997 Risk-based MRSA screening Reduce
Jun 2006 Intensive hand-hygiene training and audit Reduce Reduce
Nov 2006 Intensive audit programme for line and urinary catheter insertion
and aftercare and care bundle for ventilated patients
Reduce Reduce
Nov 2006 Root-cause analysis of all MRSA bacteraemia Reduce
Sep 2007 Clean your hands alcohol hand gel introduction Reduce Reduce
Feb 2008 Root cause analysis of all line related S aureus bacteraemia Reduce Reduce
Sep 2008 Decontamination of all patients admitted to general medicine
and gerontology (regardless of MRSA/MSSA status) using daily
Triclosan wash for ﬁrst 5 days
Reduce Reduce
Mar 2009 MRSA screening of elective admissions and decontamination
of patients who are MRSA-positive with chlorhexidine wash
and chlorhexidine/neomycin (Naseptin) nasal cream for 5 days
Reduce
Apr 2009 24 h decontamination for patients undergoing high-risk surgery
(regardless of MRSA/MSSA status) with chlorhexidine wash
and Naseptin nasal cream; chlorhexidine mouthwash added if
admitted to intensive therapy unit
Reduce Reduce
Department of health and other national targets, campaigns and reports
Dec 2003 Winning ways report (DH)
Jul 2004 Towards cleaner hospitals (DH)
Sep 2004 Clean your hands (NPSA)
Nov 2004 MRSA reduction target (DH)
Jun 2005 Saving Lives Programme (DH)
Oct 2006 Health Act 2006 (DH)
Jun 2007 Clean safe care: reducing MRSA and other healthcare-associated
interventions (DH)
Apr 2009 National elective screening (DH)
National audit ofﬁce reports
Feb 2000 NAO report
Jul 2004 NAO report
Jun 2009 NAO report
DH, Department of Health; MRSA, meticillin-resistant Staphylococcus aureus; MSSA, meticillin-sensitive Staphylococcus aureus; NAO,
National Audit Ofﬁce.
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The MRSA epidemic in acute Oxfordshire hospitals had
three phases characterised by expansion, decline and
rapid decline in isolations from blood cultures, invasive
and surface sites. The transition from expansion to
initial decline occurred signiﬁcantly before the major
anti-MRSA initiatives were deployed in these hospitals.
More rapid declines occurred after the interventions but
appeared to be driven by declines in erythromycin-
resistant MRSA, estimated to be predominantly ST36.
Throughout this period, isolations of meticillin-sensitive
S aureus did not decline substantially; observed small
increases in sensitive S. aureus from some sample types
suggestive of invasive infection may reﬂect nationally
reported trends.
21 Importantly, a large body of disease
remains across all specimen types, with rates of metic-
illin-sensitive S aureus isolation now about 10 times
higher than those of MRSA.
The rise and fall of dominant MRSA clones appear very
similar to the large, but unexplained, waves in isolation
rate seen previously with other MRSA clones
5 6, the ST22
wave following the ST36 wave. Indeed, such displace-
ment has been noted with MRSA ST36 elsewhere in
Europe
22 and is suggested by a study of MRSA collected
from multiple UK hospitals between 2001 and 2007.
8
The study has several limitations. First, it is restricted
to acute NHS hospitals in one city. However, the overall
trends in isolations in both MRSA and MSSA observed
are similar to those seen for bacteraemias in many other
UK hospitals,
10 21 23 although this detailed study allows
us to look beyond blood cultures. Second, our estimates
of incidence of MRSA strains rely on extrapolation from
antibiotic sensitivity results. Reassuringly, differential
macrolide resistance in ST22 and ST36 has been found
previously elsewhere,
8 and sensitivity analyses varying the
relationship between susceptibility and strain were
similar to the primary analysis. Further, although anti-
biotic resistance can develop within a strain,
3 this is
a rare occurrence and results in increased, not
decreased, resistance.
During the study period, there was aggressive imple-
mentation of programmes expected to reduce S aureus
disease irrespective of strain type and meticillin resis-
tance, such as the enhanced infection-control proﬁle in
the Health Act 2006, widespread use of alcohol hand
gels and alcoholic chlorhexidine, and focus on ‘high
value interventions’ such as central and peripheral line
insertion care bundles.
13 It is concerning that an impact
on both sensitive and resistant S aureus strains was not
observed, although national
24 and local audit suggested
improvements and reasonably high compliance
(80e90%) with all these interventions. In further work,
we plan to investigate their impact in the deﬁned, high-
risk settings where they were most heavily used, aiming
to estimate effects controlling for the observed waves in
MRSA isolation rate.
We conclude that alterations in MRSA isolation rates
are likely to have been inﬂuenced by biological factors
Figure 2 Rates of isolation of
erythromycin-sensitive and
meticillin-resistant Staphylococcus
aureus (MRSA) in blood cultures
(panel A). Points indicate quarterly
rates of isolation of erythromycin-
resistant and -sensitive MRSA:
solid lines are trends in each
period from negative binomial
regression. Denominators are
hospital KH03 overnight bed-stay
statistics. Broken lines are
estimated rates of isolation of
MRSA ST22 and ST36 (see
Results for assumptions). In (B),
shaded areas show upper and
lower estimates of ST22/36 rates
based on the 95% CI around the
proportion of ST22 isolates which
are erythromycin-sensitive. Panel
C shows relative change in each
time period. Evidence for variation
in trends in ﬁrst versus second and
second versus third periods
respectively: erythromycin-
resistant <0.0001, 0.001;
erythromycin-sensitive <0.0001,
0.78 (*p<0.01 for the comparison
shown). Evidence for variation between erythromycin-resistant
versus sensitive in the ﬁrst period p¼0.002;
second period p¼1.00; third period p¼0.002.
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MRSA epidemics,
5 6 at least part of the decline in the UK’s
nosocomial MRSA outbreak is probably spontaneous.
Biologically driven changes in bacterial strains and their
behaviour are well known, being documented before
in Staphylococcus pyogenes,
25 Streptococcus pneumonia
26
Neisseria meningitidis
27 as well as S aureus
56 ; immune
selection may mediate some of these changes.
28
Given the absence of effect of the interventions on
MSSA, the decline in MRSA prior to interventions, the
strain speciﬁcity of the effect on MRSA and the difﬁculty
of demonstrating the effect of an intervention package
on MRSA isolation,
14 we ﬁnd it difﬁcult to estimate how
much, if any, of the observed decline in MRSA isolations
is attributable to recent infection-control measures.
Some components of the infection control package
implemented are supported by trial evidence,
29 but
many are not.
Consequently, we suggest that the cost-effectiveness of
high-cost MRSA-speciﬁc control measures, such as
Figure 3 Rates of isolation of
erythromycin-sensitive and
resistant meticillin-resistant
Staphylococcus aureus (MRSA) in
(A) blood, (B) invasive, and
(C) surface specimens. Points
indicate quarterly rates of isolation
of erythromycin-resistant and
-sensitive MRSA: solid lines are
trends in each period from
negative binomial regression.
Denominators are hospital KH03
overnight bed-stay statistics.
Broken lines are estimated rates
of isolation of MRSA ST22 and
ST36 (see Results for
assumptions). Comparison is
made between macrolide-
sensitive and -resistant isolation
and estimated trends in ST22 and
ST36 are shown in each panel.
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Decline of meticillin-resistant Sa u r e u sin Oxfordshire hospitalsuniversal MRSA screening,
13 should be re-examined,
given assumptions of declining baseline prevalence.
They should be costed relative to programmes with
a robust evidence base,
29 reducing intravascular catheter
or surgical site S aureus disease. This and other recent
studies
2 imply that a greater emphasis on S aureus
disease, irrespective of resistance proﬁle, is required. A
positive recent development in this area is the Depart-
ment of Health’s decision to institute mandatory
surveillance of all S aureus bloodstream isolations.
30
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